Liane Rae Teplitsky Buys 1,024 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Teplitsky purchased 1,024 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was acquired at an average cost of $48.80 per share, with a total value of $49,971.20. Following the completion of the acquisition, the chief operating officer directly owned 3,094 shares in the company, valued at approximately $150,987.20. This trade represents a 49.47% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

• On Tuesday, September 1st, Liane Teplitsky acquired 1,001 shares of Pulse Biosciences stock. The shares were acquired at an average cost of $49.95 per share, with a total value of $49,999.95.
• On Friday, August 28th, Liane Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The shares were acquired at an average price of $48.35 per share, for a total transaction of $49,993.90.
• On Wednesday, August 26th, Liane Teplitsky bought 1,036 shares of Pulse Biosciences stock. The stock was acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28.

Pulse Biosciences Stock Up 3.9%

Shares of PLSE stock opened at $54.71 on Friday. The business has a 50 day moving average of $37.48 and a two-hundred day moving average of $27.82. Pulse Biosciences, Inc has a 52 week low of $12.56 and a 52 week high of $55.37. The company has a market cap of $3.79 billion, a P/E ratio of -46.36 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Pulse Biosciences in the 2nd quarter worth approximately $40,672,000. Bank of America Corp DE acquired a new stake in Pulse Biosciences in the 2nd quarter valued at approximately $40,115,000. California State Teachers Retirement System raised its stake in Pulse Biosciences by 2,600.0% during the 2nd quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock valued at $15,747,000 after acquiring an additional 546,850 shares in the last quarter. State Street Corp raised its stake in Pulse Biosciences by 6.0% during the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after acquiring an additional 25,187 shares in the last quarter. Finally, Brooklyn Investment Group boosted its position in Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after acquiring an additional 100,081 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on PLSE. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a report on Monday, August 17th. They set a “buy” rating and a $58.00 price target for the company. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research report on Monday, August 10th. Finally, Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.